FSTX yields 28.09% · MAIN yields 8.41%● Live data
📍 FSTX pulled ahead of the other in Year 1
Combined, FSTX + MAIN cover 8 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FSTX + MAIN for your $10,000?
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Full FSTX Calculator →Main Street Capital is a Business Development Company providing debt and equity capital to lower middle market companies. It pays regular monthly dividends plus semi-annual special dividends. One of the few BDCs consistently trading at a premium to NAV, with an exceptional track record since its 2007 IPO. Often called the gold standard of BDCs.
Full MAIN Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.